Sweet's syndrome and Pneumocystis carinii pneumonia: two sequelae of low-dose cytosine arabinoside therapy in a patient with acute myeloid leukemia.
Cytosine arabinoside in low dose is sometimes employed for treating acute myeloid leukaemia. We report here a case of acute myeloid leukemia, treated with low-dose cytosine arabinoside, who developed acute febrile neutrophilic dermatosis and Pneumocystis carinii pneumonia after attainment of remission. A direct effect of cytosine arabinoside on neutrophil function and an immunosuppressive potential in lower doses could be speculated.
Chowdhary
V
V
Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
Nityanand
S
S
Prasad
K N
KN
Pandey
R
R
Dabadghao
S
S
D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects; D003561:Cytarabine / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D017809:Fatal Outcome; D005334:Fever / Q000209:etiology; D006801:Humans; D016867:Immunocompromised Host; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D004915:Leukemia, Erythroblastic, Acute / Q000150:complications* / Q000188:drug therapy; D008297:Male; D009504:Neutrophils / Q000187:drug effects; D011020:Pneumonia, Pneumocystis / Q000209:etiology*; D012131:Respiratory Insufficiency / Q000209:etiology; D016463:Sweet Syndrome / Q000209:etiology*
D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine